GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Phase 3

Recruiting

Conditions: Chickenpox

Interventions: Biological: Investigational varicella vaccine_Lot 1
Biological: Investigational varicella vaccine_Lot 2
Biological: Investigational varicella vaccine_Lot 3
Biological: Marketed varicella vaccine_Lot 1
Biological: Marketed varicella vaccine_Lot 2
Biological: MMR vaccine
Biological: Hepatitis A vaccine
Biological: PCV (pneumococcal conjugate vaccine) 13
Biological: PCV 20
Biological: Vaxneuvance

First Posted Date: 2024-12-18

Last Posted Date: 2025-03-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1840

Registration Number: NCT06740630

Locations: 🇺🇸
GSK Investigational Site, Layton, Utah, United States

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

Phase 1

Recruiting

Conditions: Kidney Disease

Interventions: Drug: GSK4771261
Drug: Placebo matching GSK4771261

First Posted Date: 2024-12-16

Last Posted Date: 2025-04-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 84

Registration Number: NCT06734234

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Phase 3

Recruiting

Conditions: Bronchial Diseases

Interventions: Drug: Belimumab

First Posted Date: 2024-12-04

Last Posted Date: 2025-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 225

Registration Number: NCT06716606

Locations: 🇰🇷
GSK Investigational Site, Yongsan-Ku Seoul, Korea, Republic of

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Phase 1

Recruiting

Conditions: Neoplasms, Colorectal
Solid Tumor
Colon Cancer
Rectal Cancer
Endometrial Cancer

Interventions: Drug: GSK4418959
Biological: PD-1 inhibitor

First Posted Date: 2024-11-29

Last Posted Date: 2025-02-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 73

Registration Number: NCT06710847

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Phase 1

Recruiting

Conditions: Urinary Tract Infections

First Posted Date: 2024-11-25

Last Posted Date: 2025-05-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 448

Registration Number: NCT06702449

Locations: 🇺🇸
GSK Investigational Site, Rochester, New York, United States

A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: HFA-152A propellant
Drug: HFA-134A propellant

First Posted Date: 2024-11-25

Last Posted Date: 2025-07-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT06702462

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Phase 3

Recruiting

Conditions: Chickenpox

Interventions: Biological: Investigational varicella vaccine
Biological: Marketed varicella vaccine
Biological: Measles, mumps, and rubella vaccine
Biological: Hepatitis A vaccine
Biological: PCV (pneumococcal conjugate vaccine) 13
Biological: PCV 20
Biological: Vaxneuvance

First Posted Date: 2024-11-18

Last Posted Date: 2025-01-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 750

Registration Number: NCT06693895

Locations: 🇺🇸
GSK Investigational Site, West Covina, California, United States

A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Phase 1

Active, not recruiting

Conditions: COVID-19

Interventions: Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 2
Combination Product: Licensed Flu Seasonal
Combination Product: Flu Seasonal mRNA
Combination Product: SARS-CoV-2 mRNA Dose 1
Combination Product: SARS-CoV-2 mRNA Dose 2
Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 1
Drug: Placebo
Combination Product: Licensed COVID-19 mRNA

First Posted Date: 2024-11-08

Last Posted Date: 2025-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 107

Registration Number: NCT06680375

Locations: 🇺🇸
GSK Investigational Site, Rochester, New York, United States

A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants

Phase 1

Recruiting

Conditions: Colitis, Ulcerative

Interventions: Drug: GSK4528287
Drug: Placebo

First Posted Date: 2024-11-08

Last Posted Date: 2025-04-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 48

Registration Number: NCT06681181

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Phase 3

Recruiting

Conditions: Multiple Myeloma
Newly Diagnosed Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2024-11-07

Last Posted Date: 2025-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 520

Registration Number: NCT06679101

Locations: 🇨🇳
GSK Investigational Site, Kaohsiung, Taiwan

AI-Powered Research

Premium Access

GlaxoSmithKline

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)